^
Association details:
| Biomarker: | BTK mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug Class: | BTK inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Incidence of BTK mutations in chronic lymphocytic leukaemia treated with BTK inhibitors in a single UK institution
Published date:
01/05/2021
Excerpt:
...BTKi, which was longer (72·5 months, 56·8–79·2) with BTK mutations than without (35·8 months, 16·5–52·0, p 0·0052)...With a median follow up of 30·8 months, 36‐month overall survival (OS) was 72·8% (95% CI, 62·8–80·9) and progression‐free survival (PFS) was 69·6% (95% CI, 58·3–78·9).
